False normal von Willebrand factor activity by monoclonal antibody-based ELISA in a patient with type 2A(IID) von Willebrand disease

• References

• 1 Castaman G, Montgomery RR, Meschengieser SS. et al. von Willebrand’s disease diagnosis and laboratory issues. Haemophilia 2010; 16 (Suppl. 05) (Suppl) 67-73.
• 2 Favaloro EJ, Koutts J. Laboratory assays for von Willebrand factor: relative contribution to the diagnosis of von Willebrand’s disease. Pathology 1997; 29: 385-391.
• 3 Flood VH, Friedman KD, Gill JC. et al. Limitations of the ristocetin cofactor assay in measurement of von Willebrand factor function. J Thromb Haemost 2009; 7: 1832-1839.
• 4 Flood VH, Gill JC, Morateck PA. et al. Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor. Blood 2010; 116: 280-286.
• 5 abp von Willebrand Factor Activity Test Kit package insert. Available upon request at. http://www.abpcorp.com/activity%20kit/default.html Accessed June 28, 2011
• 6 Goodall AH, Jarvis J, Chand S. et al. An immunoradiometric assay for human factor VIII/von Willebrand factor (VIII:vWF) using a monoclonal antibody that defines a functional epitope. Br J Haematol 1985; 59: 565-577.
• 7 Murdock PJ, Woodhams BJ, Matthews KB. et al. Von Willebrand factor activity detected in a monoclonal antibody-based ELISA: an alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use. Thromb Haemost 1997; 78: 1272-1277.
• 8 Tosetto A, Rodeghiero F, Castaman G. et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 2006; 4: 766-773.
• 9 De Vleeschauwer A, Devreese K. Comparison of a new automated von Willebrand factor activity assay with an aggregation von Willebrand ristocetin cofactor activity assay for the diagnosis of von Willebrand disease. Blood Coagul Fibrinolysis 2006; 17: 353-358.
• 10 Tjernberg P. Vos HL. Spaargaren-van Riel CC. et al. Differential effects of the loss of intrachain-versus interchain-disulfide bonds in the cystine-knot domain of von Willebrand factor on the clinical phenotype of von Willebrand disease. Thromb Haemost 2006; 96: 717-724.
• 11 Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998; 67: 395-424.
• 12 Wagner DD. Lawrence SO. Ohlsson Wilhelm. et al. Topology and order of formation of interchain disulfide bonds in von Willebrand factor. Blood 1987; 69: 27-32.
• 13 Lynch DC, Williams R, Zimmerman TS. et al. Biosynthesis of the subunits of factor VIIIR by bovin aortic endothelial cells. Proc Natl Acad Sci USA 1983; 80: 2738-2742.
• 14 ISTH-SSC VWF Online Database. Available at. http://www.ragtimedesign.com/vwf/ mutation/mutationtableresults.php Accessed June 28, 2011
• 15 Preston FE. Assays for von Willebrand factor functional activity: a UK NEQAS survey. Thromb Haemost 1998; 80: 863
• 16 Favaloro EJ. Detection of von Willebrand disorder and identification of qualitative von Willebrand factor defects. Am J Clin Pathol 2000; 114: 608-618.
• 17 Nitu-Whalley IC, Riddell A, Lee CA. et al. Identification of type 2 von Willebrand disease in previously diagnosed type 1 patients: a reappraisal using phenotypes, genotypes and molecular modeling. Thromb Haemost 2000; 84: 998-1004.
• 18 Vanhoorelbeke K, Cauwenberghs N, Vauterin S. et al. A reliable and reproducible ELISA Method to measure ristocetin cofactor activity of von Willebrand factor. Thromb Haemost 2000; 83: 107-113.